EMA/415238/2024

European Medicines Agency decision

P/0345/2024

of 13 September 2024

on the agreement of a paediatric investigation plan and on the granting of a waiver for hydroxycarbamide, (EMEA-003388-PIP01-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0345/2024

of 13 September 2024

on the agreement of a paediatric investigation plan and on the granting of a waiver for hydroxycarbamide, (EMEA-003388-PIP01-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Addmedica on 17 May 2023 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 July 2024, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for hydroxycarbamide, dispersible tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for hydroxycarbamide, dispersible tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Theravia, 16 rue Montrosier, 92200 - Neuilly-sur-Seine, France.

EMA/PDCO/304405/2023
Amsterdam, 26 July 2024

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver

EMEA-003388-PIP01-23

Scope of the application

Active substance(s):

Hydroxycarbamide

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of sickle cell disease

Pharmaceutical form(s):

Dispersible tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Theravia

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Addmedica submitted for agreement to the European Medicines Agency on 17 May 2023 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 10 July 2023.

Supplementary information was provided by the applicant on 26 April 2024. The applicant proposed modifications to the paediatric investigation plan.

On 2 May 2024 Addmedica requested to transfer the paediatric investigation plan to Theravia.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with

     Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of sickle cell disease

The waiver applies to:

- the paediatric population from birth to less than 9 months of age and the paediatric population from 12 years to less than 18 years of age;
- dispersible tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of sickle cell disease

2.1.1. Indication(s) targeted by the PIP

Prevention of sickle cell disease (SCD) crises

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 9 months to less than 12 years of age

2.1.3. Pharmaceutical form(s)

Dispersible tablet

2.1.4. Measures).

Area	Description
Quality-related studies	**Study 1** Development of age-appropriate dispersible tablet containing 50 mg of hydroxycarbamide for the paediatric population from 9 months to less than 12 years of age.
Non-clinical studies	Not applicable.
Clinical studies	**Study 2** Open-label, non-comparative, multicentre study to evaluate the acceptability of a new paediatric formulation of hydroxycarbamide in children from 2 years to 6 years of age with sickle cell disease (SIK-FR-22-1).

	Study 3 Single-group, non-randomised, open-label study of a twice daily dosing regimen of hydroxycarbamide (HC) paediatric dispersible tablets in children between 9 months and less than 12 years of age with SCD who are HC-naïve [KID-BID Study (SIK-FR-24-1)].
Modelling and simulation studies	**Study 4** Modelling and simulation PopPK/PD study to predict initial paediatric doses to be used in clinical studies and to support extrapolation of efficacy of a revised administration regimen in paediatric patients from 9 months to less than 12 years of age.
Other studies	**Study 5** Analysis of existing literature data to support evidence of efficacy in the paediatric population from 9 months to less than 2 years of age.
Extrapolation plan	Studies 3, 4, 5 are part of an extrapolation plan covering the paediatric population from 9 months to less than 2 years of age, as agreed by the PDCO.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By August 2026
Deferral for one or more measures contained in the paediatric investigation plan:	No

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.